Loading...
•
Dec 31, 2023
Vistagen Q3 2024 Earnings Report
Reported financial results for the third quarter of fiscal year 2024 and provided a corporate update.
Key Takeaways
Vistagen reported a net loss of $6.3 million for the third quarter of fiscal year 2024, with cash and cash equivalents of approximately $126.6 million as of December 31, 2023. The company is progressing with clinical trials for fasedienol, itruvone, and PH80.
PALISADE-3 trial initiation for fasedienol is anticipated in 1H 2024.
PALISADE-4 trial initiation for fasedienol is anticipated in 2H 2024.
Phase 2B development is underway for itruvone for major depressive disorder.
Phase 2B development is underway for hormone-free PH80 for women's health indications.
Revenue by Segment
Forward Guidance
Vistagen is focused on advancing its clinical programs, including fasedienol, itruvone and PH80.
Positive Outlook
- On track to initiate PALISADE-3 Phase 3 trial in SAD during the first half of this year.
- Making significant progress toward Phase 2B development of itruvone for major depressive disorder.
- Continue to make significant progress toward Phase 2B development of hormone-free PH80 for women's health indications.
- PALISADE-4 trial is anticipated to be initiated in the second half of 2024.
- Either PALISADE-3 or PALISADE-4, if successful, together with the positive results from PALISADE-2, may establish substantial evidence of the effectiveness of fasedienol
Challenges Ahead
- Risks and uncertainties in the process of development and commercialization
- No guarantee that any of the Company’s drug candidates will successfully complete ongoing or future clinical trials
- No guarantee to receive regulatory approval or be commercially successful
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...